News headlines about Ekso Bionics Holdings (NASDAQ:EKSO) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ekso Bionics Holdings earned a news impact score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0664716520362 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern’s rankings:

Ekso Bionics Holdings (EKSO) traded up 1.95% during midday trading on Friday, reaching $1.57. 260,028 shares of the company’s stock were exchanged. The stock’s market capitalization is $40.49 million. Ekso Bionics Holdings has a 12-month low of $0.99 and a 12-month high of $6.38. The stock’s 50-day moving average is $1.89 and its 200-day moving average is $2.55.

A number of equities research analysts have commented on EKSO shares. Zacks Investment Research downgraded shares of Ekso Bionics Holdings from a “buy” rating to a “hold” rating in a research report on Friday, June 16th. B. Riley reaffirmed a “buy” rating and issued a $4.00 target price on shares of Ekso Bionics Holdings in a research report on Wednesday, May 10th.

COPYRIGHT VIOLATION NOTICE: “Ekso Bionics Holdings (EKSO) Getting Somewhat Positive News Coverage, Report Finds” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at

In other Ekso Bionics Holdings news, insider Russ Angold sold 221,746 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $1.55, for a total transaction of $343,706.30. Following the transaction, the insider now owns 400,678 shares in the company, valued at approximately $621,050.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.10% of the company’s stock.

Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.